SCHEMBL6665516

SCHEMBL6665516

COC(=O)[C@@H]1C[C@@H](OC)CN1C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
FKBP1A P62942 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
PREP P48147 2/20 0.45
MITF O75030 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTR2C P28335 1/20 0.44
CPB1 P15086 1/20 0.44
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 2/20 0.43
TSHR P16473 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
MMP2 P08253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005973 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL2999647 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL9098331 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL15589454 0.94 FKBP1A (0.49) POLBFKBP1ANPSR1PREPNPC1
SCHEMBL19158857 0.94 FKBP1A (0.49) POLBFKBP1ANPSR1PREPNPC1
SCHEMBL13613076 0.92 POLB (0.48) POLBFKBP1ANPSR1PREPMITF
SCHEMBL3541296 0.91 POLB (0.48) POLBFKBP1ANPSR1PREPMITF
SCHEMBL15291850 0.91 POLB (0.50) POLBFKBP1ANPSR1PREPMITF
SCHEMBL3541298 0.91 POLB (0.48) POLBFKBP1ANPSR1PREPMITF
SCHEMBL28718975 0.91 POLB (0.48) POLBFKBP1ANPSR1PREPHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-12325701-B2 YKL-40 inhibitors and their therapeutic MOLECURE S.A. (PL) 2025-06-10 US disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
EP-2578590-B1 ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOREA INST SCI & TECH (KR) 2017-08-16 EP disclosed
US-9062066-B2 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-06-23 US disclosed
US-9062066-B2 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-06-23 US disclosed
EP-2578590-A2 ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Korea Institute of Science and Technology (KR) 2013-04-10 EP disclosed
US-20130072482-A1 ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME PHAROSBIOMED CO., LTD. (KR) 2013-03-21 US disclosed
US-20130072482-A1 ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME PHAROSBIOMED CO., LTD. (KR) 2013-03-21 US disclosed
US-6833456-B2 Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors AGOURON PHARMACEUTICALS, INC. 2004-12-21 US disclosed
EP-1483268-A2 INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040019065-A1 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use ROMINES WILLIAM HENRY (US) 2004-01-29 US disclosed
WO-2003074529-A2 iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS PFIZER INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072482-A1 ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME LCK, SRC, MAP3K1 POLB 3374/4885FKBP1A 1415/4885NPSR1 2604/4885
US-20040019065-A1 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use CDKN1A, CCNA1, TYMP POLB 1557/4885FKBP1A 813/4885NPSR1 2091/4885
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA POLB 4316/4885FKBP1A 2322/4885NPSR1 2743/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 POLB 3148/4885FKBP1A 3347/4885NPSR1 1506/4885
US-12325701-B2 YKL-40 inhibitors and their therapeutic CHI3L1, CHI3L2, CHIA POLB 4381/4885FKBP1A 2235/4885NPSR1 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.